Compare · MYOK vs TRIL
MYOK vs TRIL
Side-by-side comparison of MyoKardia, Inc. (MYOK) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYOK and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL carries a market cap of $1.94B.
- TRIL has more recent analyst coverage (5 ratings vs 0 for MYOK).
- Company
- MyoKardia, Inc.
- Trillium Therapeutics Inc.
- Price
- -
- $19.30-3.45%
- Market cap
- -
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 5
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest MYOK
- FDA Approval for CAMZYOS issued to MYOKARDIA INC
- MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
- MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy
- MyoKardia Reports Third Quarter 2020 Financial Results
- Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
- MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program
- Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
- MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020
- ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - MR, MYOK, CBLI, SBPH, PTI, PRCP
- SHAREHOLDER ALERT: WeissLaw LLP Reminds MYOK, PTI, BMCH and GHIV Shareholders About Its Ongoing Investigations
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo